Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

Item

http://www.wikidata.org/entity/Q58753938

Q58753938

about

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

Item

http://www.wikidata.org/entity/Q58753938

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Systematic bias between blinde ...... nts with advanced solid tumour

@en

Systematic bias between blinde ...... nts with advanced solid tumour

@nl

type

Item

label

Systematic bias between blinde ...... nts with advanced solid tumour

@en

Systematic bias between blinde ...... nts with advanced solid tumour

@nl

prefLabel

Systematic bias between blinde ...... nts with advanced solid tumour

@en

Systematic bias between blinde ...... nts with advanced solid tumour

@nl

P1476

Systematic bias between blinde ...... nts with advanced solid tumour

@en

P2093

Difei Chen

http://www.w3.org/2001/XMLSchema#string

Hengrui Liang

http://www.w3.org/2001/XMLSchema#string

Jianxing He

http://www.w3.org/2001/XMLSchema#string

Jiaqing Zhou

http://www.w3.org/2001/XMLSchema#string

Jiaxi He

http://www.w3.org/2001/XMLSchema#string

Jiaxuan Xu

http://www.w3.org/2001/XMLSchema#string

Jieyu Wu

http://www.w3.org/2001/XMLSchema#string

Kexin Deng

http://www.w3.org/2001/XMLSchema#string

Lindsey Tristine Hamblin

http://www.w3.org/2001/XMLSchema#string

Long Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

P304

e017240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2017-017240

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jianrong Zhang

Wenhua Liang

P577

2018-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30206071

http://www.w3.org/2001/XMLSchema#string

P921

bias

P932

6144327

http://www.w3.org/2001/XMLSchema#string

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

about

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932